Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18266
Country/Region: Haiti
Year: 2018
Main Partner: GHESKIO
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $3,000,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $318,668
Care: Orphans and Vulnerable Children (HKID) $469,797
Care: TB/HIV (HVTB) $209,111
Care: Pediatric Care and Support (PDCS) $209,111
Laboratory Infrastructure (HLAB) $120,000
Strategic Information (HVSI) $80,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $42,500
Testing: HIV Testing and Counseling (HVCT) $562,778
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $146,591
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $632,333
Treatment: Pediatric Treatment (PDTX) $209,111
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 54
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 54
GEND_GBV Number of people receiving post-GBV care 2019 54
HTS_SELF 2019 1,064
HTS_SELF 15-19, Female, Directly-Assisted 2019 38
HTS_SELF 15-19, Female, Unassisted 2019 38
HTS_SELF 15-19, Male, Directly-Assisted 2019 38
HTS_SELF 15-19, Male, Unassisted 2019 38
HTS_SELF 20-24, Female, Directly-Assisted 2019 38
HTS_SELF 20-24, Female, Unassisted 2019 38
HTS_SELF 20-24, Male, Directly-Assisted 2019 38
HTS_SELF 20-24, Male, Unassisted 2019 38
HTS_SELF 25-29, Female, Directly-Assisted 2019 38
HTS_SELF 25-29, Female, Unassisted 2019 38
HTS_SELF 25-29, Male, Directly-Assisted 2019 38
HTS_SELF 25-29, Male, Unassisted 2019 38
HTS_SELF 30-34, Female, Directly-Assisted 2019 38
HTS_SELF 30-34, Female, Unassisted 2019 38
HTS_SELF 30-34, Male, Directly-Assisted 2019 38
HTS_SELF 30-34, Male, Unassisted 2019 38
HTS_SELF 35-39, Female, Directly-Assisted 2019 38
HTS_SELF 35-39, Female, Unassisted 2019 38
HTS_SELF 35-39, Male, Directly-Assisted 2019 38
HTS_SELF 35-39, Male, Unassisted 2019 38
HTS_SELF 40-49, Female, Directly-Assisted 2019 38
HTS_SELF 40-49, Female, Unassisted 2019 38
HTS_SELF 40-49, Male, Directly-Assisted 2019 38
HTS_SELF 40-49, Male, Unassisted 2019 38
HTS_SELF 50+, Female, Directly-Assisted 2019 38
HTS_SELF 50+, Female, Unassisted 2019 38
HTS_SELF 50+, Male, Directly-Assisted 2019 38
HTS_SELF 50+, Male, Unassisted 2019 38
HTS_SELF Directly-Assisted 2019 532
HTS_SELF Unassisted 2019 532
HTS_SELF Unassisted - Other 2019 176
HTS_SELF Unassisted - Self 2019 176
HTS_SELF Unassisted - Sex Partner 2019 180
HTS_TST <5, Unknown Sex, Negative 2019 249
HTS_TST 25-29, Female, Negative 2019 286
HTS_TST 25-29, Female, Negative 2019 162
HTS_TST 25-29, Female, Negative 2019 320
HTS_TST 25-29, Female, Negative 2019 724
HTS_TST 25-29, Female, Negative 2019 197
HTS_TST 25-29, Female, Negative 2019 2,425
HTS_TST 25-29, Male, Negative 2019 155
HTS_TST 25-29, Male, Negative 2019 87
HTS_TST 25-29, Male, Negative 2019 172
HTS_TST 25-29, Male, Negative 2019 106
HTS_TST 25-29, Male, Negative 2019 1,306
HTS_TST 30-34, Female, Negative 2019 2,425
HTS_TST 30-34, Female, Negative 2019 286
HTS_TST 30-34, Female, Negative 2019 162
HTS_TST 30-34, Female, Negative 2019 320
HTS_TST 30-34, Female, Negative 2019 724
HTS_TST 30-34, Female, Negative 2019 197
HTS_TST 30-34, Male, Negative 2019 1,306
HTS_TST 30-34, Male, Negative 2019 155
HTS_TST 30-34, Male, Negative 2019 87
HTS_TST 30-34, Male, Negative 2019 172
HTS_TST 30-34, Male, Negative 2019 106
HTS_TST 35-39, Female, Negative 2019 2,425
HTS_TST 35-39, Female, Negative 2019 286
HTS_TST 35-39, Female, Negative 2019 162
HTS_TST 35-39, Female, Negative 2019 320
HTS_TST 35-39, Female, Negative 2019 724
HTS_TST 35-39, Female, Negative 2019 197
HTS_TST 35-39, Male, Negative 2019 1,306
HTS_TST 35-39, Male, Negative 2019 155
HTS_TST 35-39, Male, Negative 2019 87
HTS_TST 35-39, Male, Negative 2019 172
HTS_TST 35-39, Male, Negative 2019 106
HTS_TST 40-49, Female, Negative 2019 2,423
HTS_TST 40-49, Female, Negative 2019 288
HTS_TST 40-49, Female, Negative 2019 160
HTS_TST 40-49, Female, Negative 2019 320
HTS_TST 40-49, Female, Negative 2019 724
HTS_TST 40-49, Female, Negative 2019 196
HTS_TST 40-49, Male, Negative 2019 1,308
HTS_TST 40-49, Male, Negative 2019 152
HTS_TST 40-49, Male, Negative 2019 87
HTS_TST 40-49, Male, Negative 2019 174
HTS_TST 40-49, Male, Negative 2019 106
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 38,795
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 158
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 356
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 554
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 65
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 711
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 235
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 280
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 42
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 29
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 175
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 102
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 208
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 147
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 24
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 264
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 71
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 104
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 23
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 16
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 99
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 57
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 117
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 83
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 46
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 31
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 195
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 113
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 233
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 164
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 2,013
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 89
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 28
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 19
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 120
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 70
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 142
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 101
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 348
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 238
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 1,481
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 861
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 1,763
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 1,246
HTS_TST_POS <5, Unknown Sex, Positive 2019 5
HTS_TST_POS 25-29, Female, Positive 2019 51
HTS_TST_POS 25-29, Female, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 9
HTS_TST_POS 25-29, Female, Positive 2019 18
HTS_TST_POS 25-29, Female, Positive 2019 25
HTS_TST_POS 25-29, Female, Positive 2019 73
HTS_TST_POS 25-29, Male, Positive 2019 39
HTS_TST_POS 25-29, Male, Positive 2019 27
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 5
HTS_TST_POS 25-29, Male, Positive 2019 13
HTS_TST_POS 30-34, Female, Positive 2019 73
HTS_TST_POS 30-34, Female, Positive 2019 51
HTS_TST_POS 30-34, Female, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 9
HTS_TST_POS 30-34, Female, Positive 2019 17
HTS_TST_POS 30-34, Female, Positive 2019 25
HTS_TST_POS 30-34, Male, Positive 2019 39
HTS_TST_POS 30-34, Male, Positive 2019 27
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 5
HTS_TST_POS 30-34, Male, Positive 2019 13
HTS_TST_POS 35-39, Female, Positive 2019 73
HTS_TST_POS 35-39, Female, Positive 2019 51
HTS_TST_POS 35-39, Female, Positive 2019 4
HTS_TST_POS 35-39, Female, Positive 2019 9
HTS_TST_POS 35-39, Female, Positive 2019 18
HTS_TST_POS 35-39, Female, Positive 2019 25
HTS_TST_POS 35-39, Male, Positive 2019 39
HTS_TST_POS 35-39, Male, Positive 2019 27
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 5
HTS_TST_POS 35-39, Male, Positive 2019 13
HTS_TST_POS 40-49, Female, Positive 2019 73
HTS_TST_POS 40-49, Female, Positive 2019 49
HTS_TST_POS 40-49, Female, Positive 2019 2
HTS_TST_POS 40-49, Female, Positive 2019 11
HTS_TST_POS 40-49, Female, Positive 2019 17
HTS_TST_POS 40-49, Female, Positive 2019 25
HTS_TST_POS 40-49, Male, Positive 2019 40
HTS_TST_POS 40-49, Male, Positive 2019 28
HTS_TST_POS 40-49, Male, Positive 2019 5
HTS_TST_POS 40-49, Male, Positive 2019 6
HTS_TST_POS 40-49, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 37
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 44
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 53
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 38
OVC_SERV Age/Sex: <1 2019 25
OVC_SERV Age/Sex: 1-9 2019 125
OVC_SERV Age/Sex: 10-14 Female 2019 47
OVC_SERV Age/Sex: 10-14 Male 2019 47
OVC_SERV Age/Sex: 15-17 Female 2019 47
OVC_SERV Age/Sex: 15-17 Male 2019 47
OVC_SERV By: Age/sex: 18-24 Female 2019 47
OVC_SERV By: Age/sex: 25+ Female 2019 47
OVC_SERV By: Age/sex: Male 18-24 2019 48
OVC_SERV By: Age/sex: Male 25+ 2019 48
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 528
OVC_SERV Program Completion: Active 2019 500
OVC_SERV Program Completion: Graduation 28 Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 528 2019 3,578
OVC_SERV Sum of Age/Sex disaggregates 2019 188
PMTCT_ART Already on ART at beginning of current pregnancy 2019 304
PMTCT_ART New on ART 2019 68
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 372
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 4,356
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 297
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 74
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 371
PMTCT_EID Sum of Infant Age disaggregates 2019 371
PMTCT_STAT 25-29, Female 2019 795
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 54
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 724
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 18
PMTCT_STAT 30-34, Female 2019 795
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 54
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 724
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 17
PMTCT_STAT 35-39, Female 2019 795
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 55
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 724
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 18
PMTCT_STAT 40-49, Female 2019 795
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 54
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 724
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 17
PMTCT_STAT By Age (Numerator): 15-19 2019 174
PMTCT_STAT By Age (Numerator): 20-24 2019 392
PMTCT_STAT By Age (Numerator): 50+ 2019 610
PMTCT_STAT By Number of known positives: 15-19 2019 12
PMTCT_STAT By Number of known positives: 20-24 2019 26
PMTCT_STAT By Number of known positives: 50+ 2019 41
PMTCT_STAT By Number of new negative: 15-19 2019 158
PMTCT_STAT By Number of new negative: 20-24 2019 356
PMTCT_STAT By Number of new negative: 50+ 2019 554
PMTCT_STAT By Number of new positives: 15-19 2019 4
PMTCT_STAT By Number of new positives: 20-24 2019 8
PMTCT_STAT By Number of new positives: 50+ 2019 13
PMTCT_STAT Number of new ANC and L&D clients 2019 4,356
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 4,356
PMTCT_STAT_den 25-29, Female 2019 795
PMTCT_STAT_den 30-34, Female 2019 795
PMTCT_STAT_den 35-39, Female 2019 795
PMTCT_STAT_den 40-49, Female 2019 795
PMTCT_STAT_den By Age (Denominator): <15-19 2019 174
PMTCT_STAT_den By Age (Denominator): 20-24 2019 392
PMTCT_STAT_den By Age (Denominator): 50+ 2019 610
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 10
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 213
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 7
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 125
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 355
TB_PREV By Age/Sex (Numerator): <15, Female 2019 46
TB_PREV By Age/Sex (Numerator): <15, Male 2019 31
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 927
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 541
TB_PREV IPT, Life-long ART, New, Positive 2019 1,545
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 1,545
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 1,716
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 51
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 34
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 1,030
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 601
TB_PREV_den IPT, Life-long ART, New, Positive 2019 1,716
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 66
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,303
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 43
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 760
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 2,172
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 2,172
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 66
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,303
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 43
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 760
TX_CURR 25-29, Female, Positive 2019 1,874
TX_CURR 25-29, Male, Positive 2019 1,010
TX_CURR 30-34, Female, Positive 2019 1,874
TX_CURR 30-34, Male, Positive 2019 1,010
TX_CURR 35-39, Female, Positive 2019 1,874
TX_CURR 35-39, Male, Positive 2019 1,010
TX_CURR 40-49, Female, Positive 2019 1,824
TX_CURR 40-49, Male, Positive 2019 960
TX_CURR Age/Sex: <1 2019 26
TX_CURR Age/Sex: <1-9 2019 296
TX_CURR Age/Sex: 10-14 Female 2019 115
TX_CURR Age/Sex: 10-14 Male 2019 95
TX_CURR Age/Sex: 15-19 Female 2019 269
TX_CURR Age/Sex: 15-19 Male 2019 184
TX_CURR Age/Sex: 20-24 Female 2019 1,144
TX_CURR Age/Sex: 20-24 Male 2019 666
TX_CURR Age/Sex: 50+ Female 2019 1,363
TX_CURR Age/Sex: 50+ Male 2019 964
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 16,558
TX_CURR Sum of age/sex disaggregates 2019 453
TX_NEW 25-29, Female, Positive 2019 120
TX_NEW 25-29, Male, Positive 2019 110
TX_NEW 30-34, Female, Positive 2019 120
TX_NEW 30-34, Male, Positive 2019 110
TX_NEW 35-39, Female, Positive 2019 120
TX_NEW 35-39, Male, Positive 2019 110
TX_NEW 40-49, Female, Positive 2019 120
TX_NEW 40-49, Male, Positive 2019 110
TX_NEW Breastfeeding status 2019 22
TX_NEW By Age/Sex: <1 2019 5
TX_NEW By Age/Sex: 1-9 2019 61
TX_NEW By Age/Sex: 10-14 Female 2019 20
TX_NEW By Age/Sex: 10-14 Male 2019 18
TX_NEW By Age/Sex: 15-19 Female 2019 36
TX_NEW By Age/Sex: 15-19 Male 2019 9
TX_NEW By Age/Sex: 20-24 Female 2019 54
TX_NEW By Age/Sex: 20-24 Male 2019 69
TX_NEW By Age/Sex: 50+ Female 2019 55
TX_NEW By Age/Sex: 50+ Male 2019 289
TX_NEW FSW 2019 214
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 1,536
TX_NEW Pregnancy status 2019 68
TX_NEW Sum of Age/Sex disaggregates 2019 550
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 15,960
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 430
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 48
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 287
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 33
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 8,618
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 958
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 5,027
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 559
TX_PVLS_den Denominator: Indication: Routine 2019 14,362
TX_PVLS_den Denominator: Indication: Targeted 2019 1,598
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 60
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 39
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,183
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 690
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 1,972
TX_RET Numerator by Status: Breastfeeding 2019 24
TX_RET Numerator by Status: Pregnant 2019 197
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 1,972
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 60
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 39
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,183
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 690
TX_RET_den Denominator by Status: Breastfeeding 2019 24
TX_RET_den Denominator by Status: Pregnant 2019 197
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 17,046
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 512
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 341
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 10,228
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 5,965
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 272
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 23
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 387
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 682
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 13,241
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 552
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 3,123
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 130
Cross Cutting Budget Categories and Known Amounts Total: $470,000
Key Populations: Sex Workers $100,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Gender: Gender Based Violence (GBV) $150,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Operation Research
Capacity building
Post GBV Care
Gender: Gender Equality $20,000
Changing harmful gender norms and promoting positive gender norms
Capacity building
Operation Research
Key Populations: MSM and TG $100,000
Monitoring and evaluation of MSM/TG programs
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Adolescent Girls and Young Women (AGYW) $100,000